Yan Shi-Bin, Chen Zhong-Guang, Ma De-Liang, Lyu Xin, Wang Yan-Li, Chen Shi-Bing, Jie Gui-Tao
Department of Hematology, Yishui Central Hospital of Linyi, Linyi 276400, Shandong Province,China.
Department of Clinical Pharmacy, Yishui Central Hospital of Linyi, Linyi 276400, Shandong Province,China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1415-1419. doi: 10.7534/j.issn.1009-2137.2017.05.023.
To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma.
Eighty-two cases of non-Hodgkin's lymphoma were divided into 2 groups: gemcitabine+oxaliplation(Gem+Oxa) group (42 cases) and vinorelbine+oxaliplatin(Vin+Oxa) group (40 cases) according to chemotherapy regimens. The clinical efficacy, side effects, progression-free survival situation in 2 groups were compared.
There was no significant difference on the clinical effects of 2 groups (P>0.05); The therapeutic efficacy for B cell lymphoma was higher than that for T cell lymphoma(P<0.05); The therapeutic effects for I-II stages was lower than that for III-IV stages(P<0.05); The incidences of platelet decline, nausea and vomit, peripheral nerve symptoms in Gem+Oxa group were lower than those in Vin+Oxa group(P<0.05); There was no significant difference in the median progression free survival(P>0.05).
The efficacy of GEMOX regimen for refractory non-Hodgkin's lymphoma has been confirmed to be good, it has distinct clinical curative effect, it can prolong the progression-free survival time in patients with B cell lymphoma, specially for III-IV stages. It can be used as the preferred method for the treatment of patients with refractory NHL.
探讨吉西他滨联合奥沙利铂（GEMOX）方案治疗难治性非霍奇金淋巴瘤患者的临床疗效。
82例非霍奇金淋巴瘤患者根据化疗方案分为两组：吉西他滨+奥沙利铂（Gem+Oxa）组42例和长春瑞滨+奥沙利铂（Vin+Oxa）组40例。比较两组的临床疗效、副作用、无进展生存情况。
两组临床效果差异无统计学意义（P>0.05）；B细胞淋巴瘤的治疗效果高于T细胞淋巴瘤（P<0.05）；I-II期的治疗效果低于III-IV期（P<0.05）；Gem+Oxa组血小板下降、恶心呕吐、周围神经症状的发生率低于Vin+Oxa组（P<0.05）；中位无进展生存期差异无统计学意义（P>0.05）。
GEMOX方案治疗难治性非霍奇金淋巴瘤的疗效已得到证实，临床疗效显著，可延长B细胞淋巴瘤患者尤其是III-IV期患者的无进展生存时间。它可作为难治性非霍奇金淋巴瘤患者治疗的首选方法。
